1
|
Yoo S, You D, Jeong IG, Hong B, Hong JH, Ahn H, Kim CS. Impact of Tumor Location on Local Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma: Implications for Adjuvant Radiotherapy. Clin Genitourin Cancer 2017; 15:e199-e204. [DOI: 10.1016/j.clgc.2016.07.010] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2016] [Revised: 07/12/2016] [Accepted: 07/13/2016] [Indexed: 12/21/2022]
|
2
|
Gustin P, Yossi S, Lafont M, Peyraga G, Trémolières P, Rousseau D, Cellier P, Paumier A, Martin F, Chapet O, Mesgouez-Nebout N. [Use of chemotherapy and radiotherapy in the treatment of urothelial carcinoma of the upper urinary tract]. Cancer Radiother 2015; 19:120-6. [PMID: 25770883 DOI: 10.1016/j.canrad.2014.11.012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2014] [Revised: 10/22/2014] [Accepted: 11/12/2014] [Indexed: 11/30/2022]
Abstract
Urothelial carcinomas of the upper urinary tract are rare entities. Surgery remains the mainstay of the management. The use of others therapeutic modalities is not clearly defined yet. However, the frequency of local recurrence and locoregional encourage us to evaluate the indication of adjuvant therapies. We conducted a synthesis of key data in the literature on the use of chemotherapy and radiotherapy in the treatment of urothelial carcinoma of the renal pelvis and ureter. A literature search on PubMed was performed using the following keywords (MeSH) "urothelial carcinoma", "upper urinary tract", "radiation", "chemotherapy", and adjuvant.
Collapse
Affiliation(s)
- P Gustin
- Département de radiothérapie, institut de cancérologie de l'Ouest, site Paul-Papin, 2, rue Moll, 49000 Angers, France.
| | - S Yossi
- Département de radiothérapie, institut de cancérologie de l'Ouest, site Paul-Papin, 2, rue Moll, 49000 Angers, France
| | - M Lafont
- Département de radiothérapie, institut de cancérologie de l'Ouest, site Paul-Papin, 2, rue Moll, 49000 Angers, France
| | - G Peyraga
- Département de radiothérapie, institut de cancérologie de l'Ouest, site Paul-Papin, 2, rue Moll, 49000 Angers, France
| | - P Trémolières
- Département de radiothérapie, institut de cancérologie de l'Ouest, site Paul-Papin, 2, rue Moll, 49000 Angers, France
| | - D Rousseau
- Département de radiothérapie, institut de cancérologie de l'Ouest, site Paul-Papin, 2, rue Moll, 49000 Angers, France
| | - P Cellier
- Département de radiothérapie, institut de cancérologie de l'Ouest, site Paul-Papin, 2, rue Moll, 49000 Angers, France
| | - A Paumier
- Département de radiothérapie, institut de cancérologie de l'Ouest, site Paul-Papin, 2, rue Moll, 49000 Angers, France
| | - F Martin
- Service d'urologie, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9, France
| | - O Chapet
- Département de radiothérapie, centre hospitalier Lyon-Sud, hospices civils de Lyon, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France
| | - N Mesgouez-Nebout
- Département de radiothérapie, institut de cancérologie de l'Ouest, site Paul-Papin, 2, rue Moll, 49000 Angers, France
| |
Collapse
|
3
|
Jang NY, Kim IA, Byun SS, Lee SE, Kim JS. Patterns of Failure and Prognostic Factors for Locoregional Recurrence after Radical Surgery in Upper Urinary Tract Transitional Cell Carcinoma: Implications for Adjuvant Radiotherapy. Urol Int 2013; 90:202-6. [DOI: 10.1159/000343729] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2012] [Accepted: 09/12/2012] [Indexed: 11/19/2022]
|
4
|
Dasanu CA, Ong-Bacay A, Codreanu I. Newer developments in the therapeutics of the transitional cell carcinoma of renal pelvis. J Oncol Pharm Pract 2011; 18:97-103. [DOI: 10.1177/1078155210394695] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Many of the risk factors and pathogenesis of urothelial carcinoma of the renal pelvis are similar to the ones of the more common urothelial bladder cancer. In addition, two endemic nephropathies and two inherited syndromes have been linked with the development of upper urologic cancer. Multiple synchronous or metachronous lesions throughout urinary tract are rather common and should always be sought in the management of this entity. Surgical resection is the treatment of choice in early-stage tumors. The role of adjuvant radiation and chemoradiation for carcinoma of the renal pelvis remains to be redefined, given the advent of conformal approaches and intensity modulation. In non-surgical candidates, chemotherapy remains the mainstay. Metastatic urothelial renal pelvic cancer is usually treated with combination platinum-based chemotherapy. Definitive radiation therapy should be considered in persons with locally advanced/unresectable disease, multiple comorbidities, and/or severely compromised performance status. Recently, the antifolate agent pemetrexed has demonstrated an overall response rate of circa 30% in urothelial carcinoma. New targeted agents, alone or in combination with cytotoxic drugs, are currently being tested in clinical trials and may lead to new and exciting avenues for the therapy of this disease.
Collapse
Affiliation(s)
- Constantin A Dasanu
- Department of Hematology–Oncology, St. Francis Hospital and Medical Center, Hartford, CT, USA
| | - Aileen Ong-Bacay
- Department of Pathology, St. Francis Hospital and Medical Center, Hartford, CT, USA
| | - Ion Codreanu
- Department of Nuclear Medicine, University of Pennsylvania Medical Center, Philadelphia, PA, USA
| |
Collapse
|